Zenas BioPharma, Inc. ( (ZBIO) ) has released its Q1 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, with a unique emphasis on its lead product candidate, obexelimab, a bifunctional monoclonal antibody.
In its first quarter of 2025 financial report, Zenas BioPharma highlighted several key developments, including progress in its clinical trials and strategic leadership appointments. The company is advancing its pivotal Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease and expects topline results by the end of 2025. Additionally, the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis is nearing completion, with results anticipated early in the fourth quarter of 2025.
Financially, Zenas reported a cash position of $314.2 million as of March 31, 2025, which is expected to support operations into the fourth quarter of 2026. The company also reported a license and collaboration revenue of $10 million, attributed to a sublicense agreement with Zai Lab. However, research and development expenses increased to $34.9 million, reflecting ongoing clinical development efforts, resulting in a net loss of $33.6 million for the quarter.
Zenas has strengthened its leadership team with the appointments of Lisa von Moltke, M.D., and Haley Laken, Ph.D., to key positions, enhancing its capabilities in research and development. The company also out-licensed regional rights to its thyroid eye disease program to Zai Lab, which could provide future milestone payments and royalties.
Looking ahead, Zenas BioPharma is poised to continue its clinical advancements with obexelimab and aims to leverage its strong financial position and leadership expertise to achieve its strategic goals in the autoimmune disease sector.